In May 2018, andexanet was granted accelerated approval as the sole antidote on the market for the DOACs rivaroxaban (Xarelto ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best pharma stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) received a rating ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

British pharma major AstraZeneca (LSE: AZN) has joined a near-$100 million series A and A+ financing round for Syneron Bio, a ...

AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in the US state of Maryland, aiming to support 2,600 jobs at its Frederick and Gaithersburg sites.

The move would onshore production of its rare disease products at an existing facility in Frederick and build a clinical ...

The pharmaceutical company AstraZeneca can move forward with an addition to one of the buildings on its Frederick campus, ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

Home to 4.8 billion people or 60 percent of the world’s population, Asia accounts for 50 percent of the global cancer ...

AstraZeneca's baxdrostat heads into FDA review after Phase 3 data showed strong blood pressure reductions in adults with hard ...